An edition of The drugging of the Americas (1976)

The drugging of the Americas

how multinational drug companies say one thing about their products to physicians in the United States, and another thing to physicians in Latin America

  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read

My Reading Lists:

Create a new list

Check-In

×Close
Add an optional check-in date. Check-in dates are used to track yearly reading goals.
Today

  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read

Buy this book

Last edited by MARC Bot
December 12, 2023 | History
An edition of The drugging of the Americas (1976)

The drugging of the Americas

how multinational drug companies say one thing about their products to physicians in the United States, and another thing to physicians in Latin America

  • 0 Ratings
  • 0 Want to read
  • 0 Currently reading
  • 0 Have read

In the United States, drug companies promoting their products to physicians are required by law to limit their claims to what they can prove, and to make full disclosure of all known hazards. Dr. Silverman, a noted science writer and pharmacologist, finds that many multinational drug companies are circumventing similar laws in Latin America in order to sell more of their products. The author provides detailed comparisons of the promotion of 28 separate prescription drugs in the U.S. and in Mexico, Central America, and other Latin American countries. Typically, claims for effectiveness are exaggerated in Latin America and the hazards are glossed over. This practice, denounced by Latin American medical experts and appalling even to scientists within the drug industry, is blamed for needless patient injury and death. When called upon to explain the inconsistencies in their promotional campaigns, their standard defense is "we're not breaking any laws." But some of these global companies have been breaking laws. They have been lying. In the United States, the major pharmaceutical companies have long and vociferously assailed the laws which now require them to restrict claims of efficacy of their products to those they can support with substantial scientific evidence and to inform physicians fully of all hazards. The companies argue that these rules are excessively harsh and that these laws and regulations are not necessary because the industry recognizes its social responsibilities and would live up to them, laws or no laws. The information presented here is a partial response to such an argument. It demonstrates that a problem exists and shows how some companies comport themselves when there are no restrictive laws, or when the laws are not enforced. -- from Preface.

Publish Date
Language
English
Pages
147

Buy this book

Previews available in: English

Book Details


Edition Notes

Includes bibliographical references and index.

Published in
Berkeley

Classifications

Dewey Decimal Class
614.3/5/098
Library of Congress
RM301 .S53

The Physical Object

Pagination
xiv, 147 p. ;
Number of pages
147

ID Numbers

Open Library
OL5203089M
Internet Archive
druggingofameric0000silv
LCCN
75027935
OCLC/WorldCat
2277688

Community Reviews (0)

Feedback?
No community reviews have been submitted for this work.

Lists

This work does not appear on any lists.

History

Download catalog record: RDF / JSON
December 12, 2023 Edited by MARC Bot import existing book
October 8, 2020 Edited by MARC Bot import existing book
December 6, 2018 Edited by ImportBot import existing book
November 17, 2018 Edited by MARC Bot import existing book
December 9, 2009 Created by WorkBot add works page